Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
SystImmune Inc.
SystImmune Inc.
Plexium, Inc.
Seagen Inc.
Pfizer
Coherus Oncology, Inc.
IDEAYA Biosciences
Arbele Limited
Vividion Therapeutics, Inc.
I-Mab Biopharma US Limited
Myeloid Therapeutics
Normunity AccelCo, Inc.
Memorial Sloan Kettering Cancer Center
Prelude Therapeutics
Kyowa Kirin Co., Ltd.
Novartis
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Seagen Inc.
NeoTX Therapeutics Ltd.
Blueprint Medicines Corporation
National Cancer Institute (NCI)
Inhibrx Biosciences, Inc
University of Oxford
Gossamer Bio Inc.
MacroGenics
Wake Forest University Health Sciences
Roswell Park Cancer Institute
University of Michigan
Washington University School of Medicine
University of California, San Francisco
Merck KGaA, Darmstadt, Germany
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Roswell Park Cancer Institute
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
University of Michigan
University of California, San Francisco
Case Comprehensive Cancer Center
Roger Williams Medical Center
Christiana Care Health Services